[{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Alkermes Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Lucitanib","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Clovis Oncology \/ Clovis Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Clovis Oncology \/ Clovis Oncology"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Isotope Technologies Munich","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Isotopia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Isotopia","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Isotopia"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Novartis Innovative Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Divestment","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0.68000000000000005,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Novartis Innovative Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Novartis Innovative Therapies"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"University of Heidelberg","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ University of Heidelberg","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ University of Heidelberg"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"68-Ga FAP-2286","moa":"FAP-alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Clovis Oncology \/ Clovis Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Clovis Oncology \/ Clovis Oncology"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"3B Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ 3B Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ 3B Pharmaceuticals"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ J.P. Morgan"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lucitanib","moa":"||Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lucitanib","moa":"||Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Clovis Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Evergreen Theragnostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"225-Ac FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Undisclosed","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Evergreen Theragnostics","highestDevelopmentStatusID":"1","companyTruncated":"Clovis Oncology \/ Evergreen Theragnostics"}]
Find Clinical Drug Pipeline Developments & Deals by Clovis Oncology
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target